COMMUNIQUÉS West-GlobeNewswire

Intelligent Bio Solutions Reports Fiscal 2025 First Quarter Financial Results and Operational Highlights

07/11/2024 - 14:30

Quarterly revenue increased 10% year-on-year and 20% quarter-on-quarter, marking four consecutive quarters of year-on-year growth Higher-margin, recurring cartridge revenue surpassed reader revenue as primary driver [...]

Femasys to Exhibit at the Annual AAGL 2024 Global Conference

07/11/2024 - 14:30

Premier conference focused on gynecological surgery ATLANTA, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide [...]

Ikena Oncology Reports Third Quarter 2024 Financial Results

07/11/2024 - 14:30

Strong financial position with $138 million in cash and investments at close of third quarter BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced financial [...]

CervoMed to Participate in Upcoming Investor Conferences

07/11/2024 - 14:30

BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that the Company’s Management will [...]

Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC

07/11/2024 - 14:30

Partnerships will employ Vaccinex’s ActivMAb® platform for viral display of complex antigens to enable antibody discovery ROCHESTER, N.Y., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical- [...]

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2024

07/11/2024 - 14:30

Conference Call Scheduled for Thursday, November 14, 2024 at 9:00 AM ET PORTLAND, Maine, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health [...]

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

07/11/2024 - 14:30

MB-108 (HSV-1 oncolytic virus) is active and well tolerated in patients with recurrent glioblastoma in ongoing Phase 1 clinical trial Preclinical data support a novel combination of MB-108 (HSV-1 oncolytic virus) and MB [...]

Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

07/11/2024 - 15:00

– Interim data from ongoing Phase 1 clinical trial of WTX-330, further characterizing tolerability and activity profile, to be presented at SITC Annual Meeting – – Monotherapy and combination expansion arms open and [...]

Promising cooperation between medac and chiron for the development of organ-on chip technology

07/11/2024 - 15:00

WEDEL, Germany, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Testing new substances in animals is a regulatory cornerstone of drug development. At the same time, the development of animal free testing methods is progressing. In [...]

Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

07/11/2024 - 15:02

- Interim phase 1 clinical trial update reveals the clinical potential of the tumor-activated IL-12 prodrug WTX-330, with favorable tolerability profile and encouraging efficacy signals - - Additional preclinical data [...]

Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema

07/11/2024 - 15:05

- Partnership Creates New Opportunities to Address Unmet Needs Related to Posterior Segment Eye Diseases in China - - Agreement Provides Additional Validation for Clearside’s Suprachoroidal Space (SCS ® ) Delivery [...]

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results

07/11/2024 - 15:05

Will present initial Phase 1C dose escalation data for vilastobart (XTX101), a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab, in a late-breaker poster presentation at the SITC Annual Meeting [...]

The Accumulus Platform Powers Sanofi’s Submissions to Multiple Regulators Around the World

07/11/2024 - 15:05

BURLINGAME, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Accumulus Synergy, Inc. (“Accumulus”), is revolutionizing the scalability of reliance pathways, enabling a recent submission from Sanofi to multiple national [...]

La Plateforme Accumulus soutient les soumissions de Sanofi auprès de plusieurs régulateurs mondiaux

07/11/2024 - 15:05

BURLINGAME, Californie, 07 nov. 2024 (GLOBE NEWSWIRE) -- Accumulus Synergy, Inc. (« Accumulus ») révolutionne l’évolutivité des voies de reliance, permettant à Sanofi de soumettre récemment des dossiers à plusieurs [...]

Nasdaq grants Biomerica an additional 180 days to meet listing compliance requirements

07/11/2024 - 15:09

IRVINE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a leading global provider of advanced medical diagnostics, announced that it has been granted an additional 180-day compliance period [...]

Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors

07/11/2024 - 15:15

Combination of vilastobart and atezolizumab demonstrated encouraging early evidence of anti-tumor activity, including unconfirmed partial responses observed in two patients with difficult-to-treat, immunologically “cold [...]

PharmAla to supply LaNeo MDMA for Clinical Trial at Yale

07/11/2024 - 15:20

TORONTO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of [...]

MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024

07/11/2024 - 16:00

AgenT-797 Combination with Checkpoint Inhibitors and Bispecific Engagers Expands Anti-Cancer Benefit PRAME-TCR iNKT Overcomes Challenges from Conventional TCR-T Cells in Solid Cancers NEW YORK, Nov. 07, 2024 (GLOBE [...]

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

07/11/2024 - 16:00

Phase 1 TRAVERSE Trial Demonstrated a Single Infusion of ALLO-316 Can Yield an Overall Response Rate of 50% and Confirmed Response Rate of 33% in Patients with CD70 Tumor Proportion Score (TPS) of Greater than 50% [...]